Standardized therapy summaries built around the RecompSignal Evidence Maturity Framework, outcome-specific evidence strength and transparent source quality.
Oral small-molecule GLP-1 agonist
Treatment-regimen weight changes: -7.5%, -8.4% and -11.2% across the three doses versus -2.1% placebo.
Amylin analog + GLP-1 agonist
Sponsor efficacy-estimand weight loss: 23.0% vs 25.5%; treatment-regimen estimates: 20.2% vs 23.6%. CagriSema did not demonstrate noninferiority.
GLP-1 agonism + GIP antagonism
Treatment-policy weight loss in the obesity cohort ranged from 12.3% to 16.2%, versus 2.5% with placebo.
GLP-1 + amylin receptor agonist
Sponsor reported up to 14.6% mean weight loss in the 40 mg group, versus 2.1% placebo.
Glucagon + GLP-1 dual agonist
Published phase 3 weight findings; reported MRI composition results await full appraisal.
GIP + GLP-1 receptor agonist
Pooled changes: body weight -21.3%, fat mass -33.9%, lean mass -10.9%. Approximately 75% of lost weight was fat and 25% lean tissue.
GLP-1 receptor agonist
Reported changes included fat mass -19.3% and lean mass -9.7% with semaglutide.
GIP + GLP-1 + glucagon agonist
Published DXA data in type 2 diabetes measure fat and lean changes; superior preservation or function is not established.
Growth-hormone-releasing factor analog
The evidence supports reduction of excess abdominal fat in the indicated population.
Experimental peptide
No adverse effects were reported in the two participants during the observation period.
Activin type II receptor pathway
At week 48, the high-dose combination produced -17.8 kg weight change versus -14.2 kg with semaglutide 2.4 mg (treatment-regimen estimand). Combinations reduced lean-mass loss relative to semaglutide alone.
Myostatin pathway
Sponsor reported reduced lean-mass loss with combinations versus semaglutide alone.
Selective androgen receptor modulator
This is a registered regimen, not a result. The separate QUALITY findings summarized above are sponsor-reported.
Myostatin/activin pathway
Weight, fat and lean-mass outcomes are planned; no posted results in the reviewed record.
Mitochondrial-derived peptide
Registered insulin-sensitivity study; no human findings established in the reviewed record.
Selective myostatin activation inhibitor
Between-group difference: 1.9 kg less lean-mass loss (80% CI 1.2–2.7), with similar weight loss.
Selective amylin receptor agonist
Efficacy-estimand weight reduction was approximately 20% in the 9 mg group versus 0.4% placebo.
Important: Evidence Maturity and Outcome Evidence Strength describe the development and support of an evidence base. They are not treatment-quality ratings, recommendations, or predictions of an individual result.
Short previews extend the library beyond the full Signal Cards. They identify the mechanism, status and uncertainty; detailed histories and community practice records are reserved for the expanded Therapy Atlas.
A randomized phase 2 monotherapy trial supports a scoped weight finding. Monotherapy, CagriSema and improvised combinations are distinct; evidence of weight loss is not proof of muscle preservation.
Primary source / development recordA GLP-1/glucagon dual agonist with a China approval announcement and published clinical research. Country-specific approval must remain separate from U.S. approval and from muscle-preservation claims.
Primary source / development recordA GLP-1/glucagon candidate that entered the PERFORMA Phase 3 MASH program. A planned liver-outcomes study does not establish a body-composition advantage or an approved indication.
Primary source / development recordForzinity has narrow accelerated approval for Barth syndrome based on a strength endpoint. Small open-label findings do not establish healthy-person performance, longevity or research-vial equivalence.
Primary source / development recordThe marketed fragment and full-length thymosin beta-4 must be distinguished. Repair enthusiasm does not establish clinical benefit for an injected fragment or a Wolverine blend.
Primary source / development recordTopical cosmetic research and injected systemic claims involve different routes and exposures. A skin or collagen mechanism is not proof of whole-body repair or safe injection.
Primary source / development recordA short melanocortin-related fragment studied in inflammatory models. Mouse and cell findings are useful hypotheses, not validated human gut-treatment protocols.
Primary source / development recordHuman studies of the long-acting DAC molecule measured GH and IGF-1 responses. They do not establish outcomes for similarly named no-DAC products or CJC/ipamorelin blends.
Primary source / development recordA human postoperative trial and hormone-response research differ from sleep, recovery and physique claims. Biomarker changes are not proof of useful recomposition.
Primary source / development recordSmall comparative neurological reports should be separated from healthy-person focus or enhancement claims. Sequence, route and clinical population matter.
Primary source / development recordLimited anxiety research does not establish every calm-focus claim, modified variant, route or long-term use pattern promoted in communities.
Primary source / development recordSmall human IV insomnia studies are preliminary and mixed; they do not validate community injection schedules. Public sleep accounts include perceived benefit and no effect.
Primary source / development recordCell experiments and limited human biomarker reports do not establish better sleep or longer life. Community sleep reports include benefit, loss of benefit and worse sleep. Synthetic epitalon and epithalamin remain distinct.
Primary source / development recordThe reviewed oral obesity program did not establish weight-loss benefit. Tolerability reports and community injection schedules do not establish injected efficacy or muscle preservation.
Primary source / development record